Table 4 Multivariant regression analysis of factors related to oncological outcomes.

From: No difference in oncological outcomes and perioperative complications between patients with ESRD with unilateral and bilateral UTUC receiving radical nephroureterectomy

 

OS

CSS

DFS

BRFS

HR

(95% CI)

p

HR

(95% CI)

p

HR

(95% CI)

p

HR

(95% CI)

p

Group

Unilateral RNU

1

  

1

  

1

  

1

  

Sequential unilateral RNU

0.92

0.66–1.30

0.653

0.83

0.41–1.66

0.593

0.86

0.45–1.66

0.654

1.01

0.63–1.62

0.955

Bilateral RNU

0.99

0.65–1.52

0.966

0.88

0.35–2.25

0.794

0.85

0.40–1.79

0.666

0.96

0.54–1.72

0.886

Age

 < 70

1

           

 > 70

2.60

2.00–3.39

 < 0.001**

         

Pathological stage T

pTis/pTa/pT0

1

  

1

  

1

     

pT1

1.44

0.98–2.13

0.065

2.90

0.80–10.54

0.107

1.56

0.67–3.62

0.299

   

pT2

1.78

1.18–2.69

0.006*

5.23

1.45–18.86

0.012*

2.05

0.87–4.84

0.100

   

pT3

1.75

1.17–2.63

0.007*

9.06

2.68–30.69

 < 0.001**

3.55

1.63–7.77

0.001**

   

pT4

4.77

2.58–8.80

 < 0.001**

21.64

5.52–84.87

 < 0.001**

6.78

2.29–20.09

0.001**

   

Pathological stage N

pN0

      

1

  

1

  

pN1/pN2

      

7.37

2.74–19.81

 < 0.001**

1.23

0.28–5.47

0.786

pNx

      

2.55

1.30–5.02

0.007*

2.90

1.71–4.91

 < 0.001**

Lymphovascular invasion

No

1

  

1

  

1

  

1

  

Yes

1.64

1.16–2.34

0.006*

2.54

1.42–4.53

0.002**

2.10

1.21–3.65

0.009*

1.94

1.22–3.08

0.005*

Surgical margin

Free

1

  

1

  

1

     

Positive

3.51

2.18–5.64

 < 0.001**

4.40

2.12–9.14

 < 0.001**

4.15

2.13–8.09

 < 0.001**

   
  1. BRFS bladder recurrence-free survival, CI confidence interval, CSS cancer specific survival, DFS disease-free survival, HR hazard ratio, N node, OS overall survival, RNU radical nephroureterctomy, T tumor.
  2. *p < 0.05, **p < 0.005.
Back to article page